302 related articles for article (PubMed ID: 30187578)
1. NKT cells - New players in CAR cell immunotherapy?
Kriegsmann K; Kriegsmann M; von Bergwelt-Baildon M; Cremer M; Witzens-Harig M
Eur J Haematol; 2018 Dec; 101(6):750-757. PubMed ID: 30187578
[TBL] [Abstract][Full Text] [Related]
2. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
5. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
6. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A; Courtney AN; Montalbano A; Robinson S; Liu K; Li M; Ghatwai N; Dakhova O; Liu B; Raveh-Sadka T; Chauvin-Fleurence CN; Xu X; Ngai H; Di Pierro EJ; Savoldo B; Dotti G; Metelitsa LS
Nat Med; 2020 Nov; 26(11):1686-1690. PubMed ID: 33046868
[TBL] [Abstract][Full Text] [Related]
8. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
9. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
10. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
11. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
12. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.
Harrer DC; Dörrie J; Schaft N
Hum Gene Ther; 2018 May; 29(5):547-558. PubMed ID: 29320890
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic Analysis of CAR-T Cells.
de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
Morgan MA; Schambach A
Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
[TBL] [Abstract][Full Text] [Related]
17. IL-21 Selectively Protects CD62L
Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
[TBL] [Abstract][Full Text] [Related]
18. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
19. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
20. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
